Provided by Tiger Fintech (Singapore) Pte. Ltd.

XORTX Therapeutics Inc.

1.01
+0.06016.33%
Volume:15.70K
Turnover:15.75K
Market Cap:3.26M
PE:-3.51
High:1.07
Open:0.9900
Low:0.8721
Close:0.9500
Loading ...

Company Profile

Company Name:
XORTX Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
3
Office Location:
3710 – 33rd Street NW,Alberta Beach,Alberta,Canada
Zip Code:
T2L 2M1
Fax:
- -
Introduction:
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.

Directors

Name
Position
Allen Warren Davidoff
President, Chief Executive Officer and Director
W. Bruce Rowlands
Chairman of the Board and Director
Ian McCulloch Klassen
Director
Jacqueline Le Saux
Director
Paul Joseph Van Damme
Director
William Farley
Director

Shareholders

Name
Position
Allen Warren Davidoff
President, Chief Executive Officer and Director
Amar Keshri
Chief Financial Officer